Table 1 Características of all patients (100 patients), patients with moderate-severe dyspnea after 1 month (47 patients) and after 12 months (19 patients) from hospital discharge.
From: Neuroleptics used in critical COVID associated with moderate-severe dyspnea after hospital discharge
Parameter | All patients | Patients with dyspnea after 1 month | Patients with dyspnea after 12 months |
|---|---|---|---|
Female sex N (%) | 50 (50) | 24 (51) | 13 (68.4) |
Age | 59.5 (49–67) | 63 (53-71.5) | 63 (50–73) |
Charlson index | 4 (2–5) | 4 (2-6.25) | 4.5 (3-6.75) |
Frailty pré-COVID | 3 (2–3) | 3 (2–3) | 3 (2.25-4) |
Time symptoms to hospital admission | 9 (7–12) | 9 (7–12) | 9 (6.5–11.5) |
Muscle blocker days | 2 (0–5) | 2 (0-5.5) | 1 (0-3.5) |
Fentanyl days | 5 (0–10) | 5 (0–12) | 4 (0-8.5) |
Midazolam days | 4 (0–7) | 4 (0-7.5) | 3 (0-6.5) |
Noradrenaline days | 3 (0-7.5) | 5 (0-7.5) | 2 (0-4.5) |
Cumulative corticoid dose (after conversion to dexamethasone - mg) | 60 (0-130.8) | 85 (50-186.5) | 66 (26.5-143.5) |
Cumulative neuroleptic dose (after conversion to quetiapine - mg) | 225 (0-1158) | 725 (175–1838) | 475 (12.5-2648.5) |
Time in mechanical ventilation | 6 (0-12.25) | 7 (0–14) | 11 (2–19) |
Length of stay in ICU | 12 (6–21) | 17 ( 7.5–24) | 11 (2–19) |
Length of stay in hospital | 23 (15-34.25) | 30 (20–41) | 23 (14.5–36.5) |
FVC (% of predicted) after 1 month from discharge | 71 (62-78.5) | 67.5 (52.25-76.0) | 69.5 (59.25-78.0) |
